Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may reveal hidden Alzheimer's in stroke survivors

NCT ID NCT02813434

Diagnosis Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special PET scan using florbetapir can help doctors figure out why some people develop memory and thinking problems after a stroke. The scan looks for amyloid plaques, a hallmark of Alzheimer's disease. Researchers studied 92 adults aged 40 to 80 who had a stroke and later experienced cognitive issues. The goal was to see how often Alzheimer's might be the underlying cause, which could guide better diagnosis and care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
florbetapir (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help doctors better identify whether Alzheimer's disease is causing cognitive decline after a stroke, leading to more targeted care.
What could go wrong
This is a completed Phase 3 study with 92 participants, so results are available but may not apply to all stroke survivors. The scan is for diagnosis only, not treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

92 people

The number who actually took part.

Started

Sep 2014

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients suffering of parenchymal stroke visualized by imaging (MRI), 2. patients suffering from cognitive impairment on the 6 months assessment (including GRECogVASC patients), 3. age between 40 and 80 years, 4. French-speaking, 5. reliable informant, 6. agreeing to participate in the study, 7. affiliation to a social security system, Exclusion Criteria: 1. women of childbearing potential (defined as pre-menopausal, less than 2 years postmenopausal, or not surgically sterile), or who are breast-feeding 2. history of relevant severe drug allergy or hypersensitivity, 3. patient receiving any investigational medications at least in the 30 last days, 4. stroke affecting the cerebellum, 5. mental retardation, 6. illiteracy, 7. dementia diagnosed before stroke, 8. history of schizophrenia or psychiatric illness requiring a stay for \> 2 days in a psychiatry unit, 9. persons placed under judicial protection, 10. comorbidities affecting cognition (respiratory, renal, liver, heart failure), 11. persistent disturbance of consciousness defined by a score to item 1a of the National Institute of Health Stroke Scale (NIHSS) ≤ 1, 12. contraindication to MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognition disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognition Disorders cognitive disorder dementia vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognition disorders Dementia

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.